Our Team
THE PEOPLE DEDICATED TO HELPING YOU
Carmen Ruiz-Ruiz
Researcher in neutron radiobiology
Pharmacist, immunologist, and biologist, Carmen is leading state-of-the art studies on biological effects of neutrons and their immune effects. She leads a team of enthusiasted biologists with experience on neutron irradiation experiments in international facilities, as the Institute Laue-Langevin (Grenoble, France), where her group mantains a biological lab in the experimental hall of the reactor.
Rosario Núñez
Researcher in Boron Chemistry
Rosario is one of the most experienced and renowned
boron chemistry researchers, particularly oriented to the development of boron-rich compounds and nanoparticles for Boron Neutron Capture Therapy.
Ignacio Porras
CSO
Expert on neutron sources and Monte Carlo simulation
Ignacio formed the first interdisciplinary research group on BNCT in Spain. He has obtained the Singular Projects 2016 prize from the Spanish Society Against Cancer and is currently the Vice-president of the International Society for Neutron Capture Therapy (ISNCT).
José Alfonso Nebrera
CEO
Cristina Aguilera Xiol
COO
Cristina is an experienced Manager with a PhD in Biomedicine and an MBA in Biotechnology Management. Proficient in leading international clinical and research projects, coordinating multidisciplinary teams, and managing R&D centers. Extensive expertise in Oncology and Genomics, gained through roles at top academic institutions, major pharmaceutical companies, and public-private partnerships.
Miquel Nuez-Martínez
Miquel is a postdoctoral research working in the I+D of innovative boron-rich compounds for Boron Neutron Capture Therapy. He is a very experienced boron chemist with great skills for the synthesis and characterization of different componds based in boron clusters,
Maria Isabel Porras-Quesada
Our youngest scientist doing her industrial doctorate in the biological response to BNCT, specially with new compounds, from both the metabolic and specific receptors approach. She has strong skills in testing new boron compounds, from the citoxicity and tumor uptake to the biological response to neutron irradiation with different biological end points.